Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Net Cash Flow (2024 - 2025)

Kairos Pharma (KAPA) has disclosed Net Cash Flow for 2 consecutive years, with -$582000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Net Cash Flow fell 2963.16% year-over-year to -$582000.0, compared with a TTM value of $3.0 million through Jun 2025, changed N/A, and an annual FY2024 reading of $1.2 million, up 442.73% over the prior year.
  • Net Cash Flow was -$582000.0 for Q2 2025 at Kairos Pharma, down from $2.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $3.2 million in Q3 2024 and bottomed at -$1.9 million in Q4 2024.